p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
暂无分享,去创建一个
Yurii B. Shvetsov | A. Whittemore | A. Talhouk | A. Hein | E. Goode | N. Traficante | S. Fereday | A. deFazio | D. Bowtell | B. Karlan | J. Benítez | N. Le | A. Berchuck | D. Huntsman | P. Pharoah | M. Köbel | M. Jimenez-Linan | J. Brenton | C. Gilks | M. Anglesio | A. Brooks-Wilson | L. Wilkens | A. Gentry-Maharaj | M. Widschwendter | M. Shah | S. Orsulic | M. Goodman | A. Swerdlow | A. Jakubowska | J. Lubiński | M. Schoemaker | S. Gayther | Chen Wang | A. Osorio | L. Paz-Ares | T. Longacre | L. Kelemen | I. Campbell | T. Ramón Y Cajal | J. Schildkraut | F. Modugno | M. Ruebner | M. El-Bahrawy | P. Ghatage | A. Hartkopf | R. Fortner | M. Carney | R. Erber | J. Lester | C. Cybulski | H. Harris | J. Rothstein | W. Sieh | Raghwa N. Sharma | S. Winham | B. Hernandez | L. Cook | J. Gronwald | Stewart G. Martin | E. Elishaev | Cheng-Han Lee | S. Ramus | H. Steed | P. Fasching | P. Coulson | Y. Shvetsov | K. Sundfeldt | Marjorie J. Riggan | P. Harnett | J. Hendley | Britta Ney | A. Staebler | S. Kommoss | A. Olawaiye | S. Storr | Helena Gronwald | S. Deen | F. J. Candido dos Reis | N. S. Meagher | J. Alsop | A. Brand | J. Koziak | Yajue Huang | M. Lycke | P. Rambau | T. Kluz | J. Boros | G. Nelson | A. Fischer | E. Kang | M. Grube | M. Courtney-Brooks | M. Boisen | Usha Menon | Christiani Bisinotto | C. Mateoiu | Arantzazu Barquín-García | Ashley Weir | A. Hartmann | V. Mcguire | K. Cushing-Haugen | Jaime Lesnock | Gregg Nelson | Jennifer A. Doherty | Bryan M McCauley | N. Singh | Catherine J Kennedy | M. Beckmann | María J. García | Mark E. Sherman | María J García | Michael E. Jones | Michael E. Jones | M. Riggan | J. Doherty | Catherine J. Kennedy
[1] Sebastian M. Armasu,et al. Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] P. Vahteristo,et al. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma. , 2022, Gynecologic oncology.
[3] Yurii B. Shvetsov,et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas , 2021, The Journal of pathology.
[4] Sebastian M. Armasu,et al. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma , 2021, Cancer Epidemiology, Biomarkers & Prevention.
[5] M. Köbel,et al. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features , 2021, The journal of pathology. Clinical research.
[6] N. Le,et al. Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype , 2021, The American journal of surgical pathology.
[7] R. L. Hollis,et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification , 2021, npj Precision Oncology.
[8] K. Garg,et al. Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains , 2021, The American journal of surgical pathology.
[9] J. Reis-Filho,et al. Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases , 2021, Modern Pathology.
[10] M. Köbel,et al. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[11] M. Köbel,et al. SWI/SNF‐deficiency defines highly aggressive undifferentiated endometrial carcinoma , 2020, The journal of pathology. Clinical research.
[12] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Talhouk,et al. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma , 2020, Clinical Cancer Research.
[14] N. Kushlinskii,et al. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer , 2020, Frontiers in Oncology.
[15] P. Fasching,et al. Prognostic gene expression signature for high-grade serous ovarian cancer , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] N. Le,et al. Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma , 2020, The journal of pathology. Clinical research.
[17] J. López-Guerrero,et al. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma , 2020, The American journal of surgical pathology.
[18] R. L. Hollis,et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome , 2020, Nature Communications.
[19] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[20] M. Köbel,et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.
[21] S. Nofech-Mozes,et al. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma , 2019, The American journal of surgical pathology.
[22] G. Mills,et al. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers , 2019, British Journal of Cancer.
[23] R. L. Hollis,et al. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma , 2019, Gynecologic oncology.
[24] N. Le,et al. Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions , 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[25] Dale W. Garsed,et al. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype , 2019, Clinical Cancer Research.
[26] A. Talhouk,et al. Nuclear β‐catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome , 2019, Histopathology.
[27] S. Nofech-Mozes,et al. FIGO Versus Silverberg Grading Systems in Ovarian Endometrioid Carcinoma: A Comparative Prognostic Analysis , 2019, The American journal of surgical pathology.
[28] Igor Jurisica,et al. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses , 2019, International Journal of Gynecologic Cancer.
[29] Sebastian M. Armasu,et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study , 2018, The journal of pathology. Clinical research.
[30] A. Whittemore,et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.
[31] Oliver Hofmann,et al. Copy-number signatures and mutational processes in ovarian carcinoma , 2017, Nature Genetics.
[32] S. Nofech-Mozes,et al. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups , 2017, Modern Pathology.
[33] M. Köbel,et al. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications , 2017, International journal of molecular sciences.
[34] N. Rosenfeld,et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.
[35] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[36] I. Shih,et al. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[37] K. Thiel,et al. TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma , 2014, International journal of oncology.
[38] R. Kurman,et al. WHO classification of tumours of female reproductive organs , 2014 .
[39] I. Sohn,et al. Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma , 2013, PloS one.
[40] A. Whittemore,et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.
[41] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[42] Gord Glendon,et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .
[43] A. Reuss,et al. The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.
[44] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[45] Joshua Labaer,et al. p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[46] D. Huntsman,et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.
[47] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[48] Nhu Le,et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. , 2008, Human pathology.
[49] D. Huntsman,et al. Critical molecular abnormalities in high-grade serous carcinoma of the ovary , 2008, Expert Reviews in Molecular Medicine.
[50] A. Malpica. Grading of ovarian cancer: a histotype-specific approach. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[51] S. Silverberg. Toward the development of a universal grading system for ovarian epithelial carcinoma. , 1999, Gynecologic oncology.